Jaguar Health (JAGX) EBITDA (2014 - 2026)

Jaguar Health (JAGX) has 13 years of EBITDA data on file, last reported at $10.2 million in Q1 2026.

• EBITDA for Q1 2026 came in at $10.2 million, up 208.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$26.3 million (up 17.89% YoY), and the FY2025 annual result was -$45.9 million, down 48.9% from the prior year.
• EBITDA improved to $10.2 million in Q1 2026 per JAGX's latest filing, from -$21.2 million in the prior quarter.
• Over five years, EBITDA peaked at $10.2 million in Q1 2026 and troughed at -$21.2 million in Q4 2025.
• A 5-year average of -$8.0 million and a median of -$8.1 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2025 and 2026: EBITDA plunged 160.41% in 2025, then soared 208.08% in 2026.
• A 5-year view of EBITDA shows it stood at -$6.3 million in 2022, then slipped by 20.22% to -$7.6 million in 2023, then fell by 7.94% to -$8.2 million in 2024, then tumbled by 160.41% to -$21.2 million in 2025, then surged by 147.93% to $10.2 million in 2026.
• Business Quant data shows JAGX's EBITDA at $10.2 million in Q1 2026, -$21.2 million in Q4 2025, and -$7.2 million in Q3 2025.